The amount of decreased HbA1c following bariatric surgery is one of the most clinically significant outcomes of metabolic intervention for type 2 diabetes. Bariatric procedures — including Roux-en-Y gastric bypass and sleeve gastrectomy — can produce substantial, sustained reductions in HbA1c through hormonal, anatomical, and weight-related mechanisms. This article explores the expected magnitude of HbA1c improvement, how different procedures compare, which patient factors influence outcomes, and what UK guidelines say about surgical eligibility and post-operative monitoring.

How Bariatric Surgery Affects Blood Glucose and HbA1c Levels

Bariatric surgery improves glycaemic control through multiple mechanisms — including increased GLP-1 secretion, reduced hepatic glucose output, and decreased insulin resistance — with some effects occurring within days of the procedure, before significant weight loss.

Have any more questions about this? Message our pharmaceutical team to get more info →

Bariatric surgery produces profound changes in glucose metabolism that extend well beyond the effects of weight loss alone. The mechanisms through which these procedures improve glycaemic control are multifactorial and, in some cases, occur within days of surgery — long before significant weight reduction has taken place.

The primary pathways include:

• Caloric restriction and reduced energy intake, which immediately lowers hepatic glucose output

• Altered gut hormone secretion, particularly increased glucagon-like peptide-1 (GLP-1) and peptide YY (PYY); GLP-1 stimulates pancreatic beta-cell insulin secretion and suppresses glucagon, contributing to improved postprandial glucose control

• Changes to bile acid metabolism, which are proposed to activate receptors involved in glucose regulation — though the precise mechanisms remain an area of active research

• Reduced adipose tissue mass over time, which decreases systemic insulin resistance

In procedures such as Roux-en-Y gastric bypass (RYGB), the rerouting of the small intestine leads to exaggerated postprandial GLP-1 responses. These incretin effects are thought to be a key driver of early glycaemic improvement, with broader gains in insulin sensitivity following progressive weight loss.

HbA1c — a measure of average blood glucose over the preceding two to three months — reflects these sustained improvements. As fasting and postprandial glucose levels normalise following surgery, HbA1c falls progressively. In patients with type 2 diabetes, this reduction can be substantial, with many achieving levels consistent with remission. Understanding these mechanisms helps clinicians and patients set realistic expectations and plan appropriate post-operative monitoring.

Expected Reductions in HbA1c After Bariatric Surgery

Bariatric surgery produces mean HbA1c reductions of approximately 15–30 mmol/mol (1.5–3%) in the first year, with diabetes remission achieved in 50–80% of patients depending on the procedure and baseline characteristics.

Clinical evidence consistently demonstrates that bariatric surgery produces substantial and durable reductions in HbA1c among patients with type 2 diabetes. The magnitude of improvement varies depending on the procedure performed, baseline HbA1c, duration of diabetes, and individual patient factors.

On average, published studies and systematic reviews report the following outcomes:

• Mean HbA1c reductions of approximately 15–20 mmol/mol (around 1.5–2%) in the first year following surgery

• The landmark STAMPEDE trial (published in the New England Journal of Medicine) reported mean HbA1c reductions of up to 25–30 mmol/mol (approximately 2.5–3%) at one year in patients undergoing RYGB or sleeve gastrectomy compared with intensive medical therapy alone; these figures reflect patients with higher baseline HbA1c values and should be interpreted in that context

• Diabetes remission — defined as HbA1c below 48 mmol/mol (6.5%) without glucose-lowering medication for at least three months, in line with the 2021 international consensus statement (ADA/EASD/Endocrine Society/Diabetes UK) — is achieved in approximately 50–80% of patients within the first one to two years post-operatively, depending on the procedure

Longer-term data, including from the Swedish Obese Subjects (SOS) study, suggest that while some patients experience a degree of glycaemic relapse over five to ten years, a significant proportion maintain substantially lower HbA1c levels compared with pre-operative values.

Important limitation: HbA1c may be less reliable in the first three months after surgery and in patients who develop iron deficiency anaemia — a common nutritional consequence of bariatric procedures. In these circumstances, fasting plasma glucose or continuous glucose monitoring (CGM) may provide more accurate assessment of glycaemic status.

These figures represent population-level averages. Individual outcomes vary considerably, and patients should be counselled that surgery is a powerful tool but not a guaranteed cure. Ongoing lifestyle modification and medical follow-up remain essential components of long-term diabetes management after bariatric intervention.

Which Procedures Produce the Greatest HbA1c Improvement

RYGB produces the greatest HbA1c reductions and highest remission rates (60–80% at one year), followed by sleeve gastrectomy and OAGB; adjustable gastric banding offers the most modest glycaemic benefit.

Not all bariatric procedures are equal in their impact on glycaemic control. The degree of HbA1c reduction is closely linked to the anatomical changes each operation produces and the resulting hormonal and metabolic effects.

Roux-en-Y gastric bypass (RYGB) is generally considered the gold standard for glycaemic improvement. By bypassing the duodenum and proximal jejunum, RYGB produces the most pronounced incretin response, leading to the greatest and most rapid reductions in HbA1c. Remission rates of 60–80% have been reported at one year in published trials and meta-analyses.

Sleeve gastrectomy removes approximately 80% of the stomach. Its mechanisms are multifactorial, including reductions in ghrelin secretion, incretin changes, and altered bile acid signalling. It produces meaningful HbA1c reductions — typically slightly less than RYGB — with remission rates of around 50–70% at one year. Its comparatively simpler surgical technique makes it a widely performed option in the UK.

One-anastomosis gastric bypass (OAGB, also known as mini gastric bypass) is performed in some UK centres and produces metabolic effects broadly comparable to RYGB, with similar or slightly higher remission rates in some studies. It is recognised by the British Obesity and Metabolic Surgery Society (BOMSS) as an accepted procedure, though practice varies between centres.

Biliopancreatic diversion with duodenal switch (BPD/DS) produces the most pronounced metabolic effects and the highest reported remission rates (up to 90% in some series), but carries greater nutritional risks and is less commonly performed in the UK. Remission rates across procedures should be interpreted with caution, as definitions and follow-up durations vary between studies.

Adjustable gastric banding produces more modest HbA1c reductions, largely mediated through weight loss rather than hormonal mechanisms, and has fallen out of favour in many UK centres.

In summary:

• RYGB and OAGB > Sleeve gastrectomy > Gastric banding in terms of HbA1c reduction

• BPD/DS offers the highest remission rates but with greater surgical and nutritional risk

The choice of procedure should be individualised, taking into account the patient's BMI, diabetes severity, comorbidities, and surgical risk profile, in discussion with a specialist multidisciplinary team (MDT).

Factors That Influence HbA1c Outcomes After Surgery

Shorter diabetes duration (under five years), lower baseline HbA1c, and absence of insulin therapy are the strongest pre-operative predictors of achieving diabetes remission after bariatric surgery.

Whilst bariatric surgery consistently improves glycaemic control, the extent of HbA1c reduction and the likelihood of achieving diabetes remission are influenced by several pre-operative and post-operative factors. Identifying these variables helps clinicians counsel patients appropriately and optimise outcomes.

Pre-operative factors associated with greater HbA1c improvement include:

• Shorter duration of type 2 diabetes — patients diagnosed within five years of surgery have significantly higher remission rates, reflecting better preserved beta-cell function; this is one of the most consistently reported predictors across meta-analyses

• Lower baseline HbA1c — those with less severe hyperglycaemia at baseline are more likely to achieve remission thresholds

• Fewer or no glucose-lowering medications pre-operatively, particularly absence of insulin therapy

• Younger age at the time of surgery

• Higher BMI — greater weight loss may contribute to improved insulin sensitivity, though the relationship between baseline BMI and glycaemic outcomes is variable across studies and should not be overstated

Post-operative factors that sustain glycaemic improvement include:

• Adherence to dietary recommendations and long-term lifestyle changes

• Regular physical activity

• Ongoing engagement with specialist follow-up services

• Avoidance of weight regain

Conversely, patients with long-standing diabetes (over ten years), those requiring insulin, or those with significant beta-cell failure are less likely to achieve full remission, though they may still experience clinically meaningful HbA1c reductions and a reduced medication burden.

Psychological readiness and understanding of post-operative dietary requirements are also important determinants of success. Pre-operative education and psychological assessment are integral components of NHS bariatric pathways, as outlined in BOMSS guidance and NHS England commissioning policies, and play a valuable role in preparing patients for sustainable outcomes.

NICE Guidelines on Bariatric Surgery for Type 2 Diabetes

NICE CG189 recommends expedited bariatric surgery assessment for adults with BMI ≥35 kg/m² and recent-onset type 2 diabetes, with BMI thresholds reduced by 2.5 kg/m² for people of Asian family origin.

In the United Kingdom, the National Institute for Health and Care Excellence (NICE) provides clear guidance on the use of bariatric surgery in the management of type 2 diabetes and obesity. The key reference is NICE CG189 (Obesity: identification, assessment and management), supported by NICE QS127 and NICE NG28 (Type 2 diabetes in adults: management).

NICE CG189 recommends the following in relation to type 2 diabetes:

• For adults with a BMI of 35 kg/m² or above and a recent-onset type 2 diabetes diagnosis (within ten years), expedited assessment for bariatric surgery should be offered; surgery may be considered as a first-line option for diabetes management in this group, rather than only after all non-surgical measures have been exhausted

• For adults with a BMI of 30–34.9 kg/m² and recent-onset type 2 diabetes, surgery should also be considered

• For people of Asian family origin, BMI action thresholds are reduced by 2.5 kg/m² across all categories, reflecting higher metabolic risk at lower BMI values (e.g., expedited assessment from BMI ≥32.5 kg/m²)

• All patients must be assessed as fit for anaesthesia and surgery, and must commit to long-term follow-up

NICE emphasises that bariatric surgery should be performed within a specialist multidisciplinary team (MDT) setting, including bariatric surgeons, dietitians, psychologists, and diabetes specialists. Pre-operative assessment, patient education, and structured post-operative follow-up are considered integral to safe and effective care.

It is important to note that local NHS commissioning policies apply and may affect access in some areas, though these should align with NICE criteria. The NHS Long Term Plan has further highlighted the role of metabolic surgery in reducing the burden of type 2 diabetes. Patients interested in surgical options should be referred through their GP to a specialist obesity service, where eligibility and suitability can be formally assessed.

Monitoring HbA1c and Diabetes Remission Following Surgery

HbA1c should be measured at three, six, and twelve months post-operatively, then annually; glucose-lowering medications must be reviewed promptly to avoid hypoglycaemia as glycaemic control improves.

Following bariatric surgery, structured monitoring of HbA1c and overall glycaemic status is essential to assess treatment response, guide medication adjustments, and identify patients who may experience glycaemic relapse over time.

Recommended post-operative monitoring typically includes:

• HbA1c measurement at three months, six months, and twelve months post-operatively, then annually thereafter, in line with BOMSS and NICE guidance (individual centre protocols may vary)

• Fasting glucose monitoring, particularly in the early post-operative period — noting that HbA1c may be less reliable in the first three months after surgery or in the presence of iron deficiency anaemia; fasting plasma glucose or CGM may be used as adjuncts in these circumstances

• Regular review of glucose-lowering medications, with prompt dose reduction or discontinuation as glycaemic control improves — this is critical to avoid hypoglycaemia

• Monitoring for reactive (postprandial) hypoglycaemia, which can occur following RYGB and OAGB due to exaggerated GLP-1 responses; patients experiencing symptoms should be referred promptly to their diabetes team for dietary review and further assessment

Perioperative medication safety: Patients taking SGLT2 inhibitors (such as dapagliflozin, empagliflozin, or canagliflozin) should have these withheld for at least three days before surgery due to the risk of euglycaemic diabetic ketoacidosis (DKA), even when blood glucose appears normal. These medicines should only be restarted once the patient is eating and drinking normally post-operatively. This is in line with guidance from the Centre for Perioperative Care (CPOC) and MHRA advice. Patients and healthcare professionals should discuss any changes to diabetes medicines with the surgical and diabetes teams before the operation.

Diabetes remission is defined, in accordance with the 2021 international consensus statement (ADA/EASD/Endocrine Society/Diabetes UK), as an HbA1c below 48 mmol/mol (6.5%) in the absence of glucose-lowering therapy, sustained for at least three months. Remission does not mean cure — ongoing monitoring remains necessary, as weight regain, dietary non-adherence, or intercurrent illness can lead to glycaemic relapse.

Patients should contact their GP or diabetes team if they experience:

• Symptoms of hypoglycaemia (shakiness, sweating, confusion, or palpitations)

• Rising blood glucose levels or return of diabetic symptoms

• Difficulty adhering to dietary recommendations

If you believe you have experienced an adverse effect from a medicine or medical device, this can be reported via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk. Reporting helps improve the safety of medicines and devices for everyone.

Long-term follow-up within a specialist bariatric or diabetes service is strongly recommended. Bariatric surgery represents a powerful intervention, but its benefits are best sustained through ongoing partnership between the patient and their healthcare team.

Frequently Asked Questions